Mon Dec 02 06:43:32 UTC 2024: ## Maravai LifeSciences Stock Dips Amidst Mixed Analyst Ratings

**Sioux Falls, SD – November 17, 2024** – Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) experienced a 3.5% decline in midday trading on Friday, closing at $5.71 after hitting a low of $5.67. Trading volume was significantly lower than average, at 220,684 shares compared to the typical 2,255,906.

The price drop comes amidst a flurry of recent analyst activity. While some firms maintain a positive outlook, others have expressed more cautious sentiment. Robert W. Baird lowered its price target to $9.00 while maintaining an outperform rating, and Royal Bank of Canada reduced its target to $13.00, also keeping an outperform rating. Conversely, Morgan Stanley downgraded the stock from overweight to equal weight, slashing its price target from $11.00 to $10.00. UBS Group, however, raised its price target from $8.50 to $11.00, though maintaining a neutral rating. Wolfe Research initiated coverage with a peer perform rating.

Despite the mixed reviews, the overall consensus rating remains a Moderate Buy, with a consensus price target of $10.33 according to MarketBeat. Six analysts rate the stock as a buy, while five have a hold rating.

Adding to the complexity, insider Carl Hull purchased 175,000 shares on November 11th at an average price of $5.64, representing a significant increase in his holdings. Meanwhile, institutional investors have also been active, with Point72 DIFC Ltd, Point72 Asset Management L.P., Mackenzie Financial Corp, Dragoneer Investment Group LLC, and Renaissance Technologies LLC all making adjustments to their stakes in the company during recent quarters. Currently, institutional investors own 50.25% of the company’s stock.

Maravai LifeSciences, a life sciences company, provides products crucial for biopharmaceutical development, including nucleic acids, antibody-based products, and protein detection tools. The company boasts a market cap of $1.43 billion and a current ratio of 10.74. However, its P/E ratio stands at a negative -3.46.

Read More